Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Sikander Ailawadhi, Yifan Zhai, Asher Chanan‐Khan et al.|Clinical Cancer Research|2023

Cited by 38